본문 바로가기
KERD
논문KCI 등재

Immunotherapy for Non-small-cell Lung Cancer: Current Status and Future Obstacles

조주환
대한면역학회 (The Korean Association of Immunologists)|2017.12|Immune Network|제17권 제6호|pp. 378-391|DOI https://doi.org/10.4110/in.2017.17.6.378

3

조회

0

다운로드

5

인용

0

참고문헌

키워드

Lung cancerImmunotherapyImmune checkpoint blockadeNSCLCNeoantigen-specific vaccines

초록

Lung cancer is one of the leading causes of death worldwide. There are 2 major subtypes of lung cancer, non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). Studies show that NSCLC is the more prevalent type of lung cancer that accounts for approximately 80%–85% of cases. Although, various treatment methods, such as chemotherapy, surgery, and radiation therapy have been used to treat lung cancer patients, there is an emergent need to develop more effective approaches to deal with advanced stages of tumors. Recently, immunotherapy has emerged as a new approach to combat with such tumors. The development and success of programmed cell death 1 (PD-1)/program death-ligand 1 (PD-L1) inhibitors and cytotoxic T-lymphocyte antigen 4 (CTLA-4) blockades in treating metastatic cancers opens a new pavement for the future research. The current mini review discusses the significance of immune checkpoint inhibitors in promoting the death of tumor cells. Additionally, this review also addresses the importance of tumor-specific antigens (neoantigens) in the development of cancer vaccines and major challenges associated with this therapy. Immunotherapy can be a promising approach to treat NSCLC because it stimulates host's own immune system to recognize cancer cells. Therefore, future research should focus on the development of new methodologies to identify novel checkpoint inhibitors and potential neoantigens.

Abstract

Lung cancer is one of the leading causes of death worldwide. There are 2 major subtypes of lung cancer, non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). Studies show that NSCLC is the more prevalent type of lung cancer that accounts for approximately 80%–85% of cases. Although, various treatment methods, such as chemotherapy, surgery, and radiation therapy have been used to treat lung cancer patients, there is an emergent need to develop more effective approaches to deal with advanced stages of tumors. Recently, immunotherapy has emerged as a new approach to combat with such tumors. The development and success of programmed cell death 1 (PD-1)/program death-ligand 1 (PD-L1) inhibitors and cytotoxic T-lymphocyte antigen 4 (CTLA-4) blockades in treating metastatic cancers opens a new pavement for the future research. The current mini review discusses the significance of immune checkpoint inhibitors in promoting the death of tumor cells. Additionally, this review also addresses the importance of tumor-specific antigens (neoantigens) in the development of cancer vaccines and major challenges associated with this therapy. Immunotherapy can be a promising approach to treat NSCLC because it stimulates host's own immune system to recognize cancer cells. Therefore, future research should focus on the development of new methodologies to identify novel checkpoint inhibitors and potential neoantigens.

참고문헌 (75)

  1. Molina JR, "Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship", Mayo Clin Proc, 83, pp.584~594 (2008)
  2. Malhotra J, "Current state of immunotherapy for non-small cell lung cancer", Transl Lung Cancer Res, 6, pp.196~211 (2017)
  3. Zappa C, "Non-small cell lung cancer: current treatment and future advances", Transl Lung Cancer Res, 5, pp.288~300 (2016)
  4. Sher T, "Small cell lung cancer", Mayo Clin Proc, 83, pp.355~367 (2008)
  5. Jackman DM, "Small-cell lung cancer", Lancet, 366, pp.1385~1396 (2005)
  6. Gulley JL, "Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: a phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy", J Clin Oncol, 33(Suppl), pp.abstr8034~ (2015)
  7. Yasumoto K, "Lung cancer-associated tumor antigens and the present status of immunotherapy against non-small-cell lung cancer", Gen Thorac Cardiovasc Surg, 57, pp.449~457 (2009)
  8. Raez LE, "Allogeneic vaccination with a B7.1 HLA-A gene-modified adenocarcinoma cell line in patients with advanced non-small-cell lung cancer", J Clin Oncol, 22, pp.2800~2807 (2004)
  9. Wang J, "Strengths and weaknesses of immunotherapy for advanced non-small-cell lung cancer: a meta-analysis of 12 randomized controlled trials", PLoS One, 7, pp.e32695~ (2012)
  10. Schiller JH, "Johnson DHEastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer", N Engl J Med, 346, pp.92~98 (2002)
  11. Khanna P, "Immunotherapy comes of age in lung cancer", Clin Lung Cancer, 18, pp.13~22 (2017)
  12. Dunn GP, "The three Es of cancer immunoediting", Annu Rev Immunol, 22, pp.329~360 (2004)
  13. Vesely MD, "Natural innate and adaptive immunity to cancer", Annu Rev Immunol, 29, pp.235~271 (2011)
  14. Swann JB, "Immune surveillance of tumors", J Clin Invest, 117, pp.1137~1146 (2007)
  15. Forde PM, "What lies within: novel strategies in immunotherapy for non-small cell lung cancer", Oncologist, 18, pp.1203~1213 (2013)
  16. Buchbinder EI, "CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition", Am J Clin Oncol, 39, pp.98~106 (2016)
  17. Wilkes DS, "Immunobiology of Organ Transplantation", pp.2004, Kluwer Academic
  18. Ott PA, "Combination immunotherapy: a road map", J Immunother Cancer, 5, pp.16~ (2017)
  19. Parry RV, "CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms", Mol Cell Biol, 25, pp.9543~9553 (2005)
  20. Kondo Y, "Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma", Oral Oncol, 57, pp.54~60 (2016)
  21. Obeid JM, "PD-L1, PD-L2 and PD-1 expression in metastatic melanoma: correlation with tumor-infiltrating immune cells and clinical outcome", Oncoimmunology, 5, pp.e1235107~ (2016)
  22. Garcia-Diaz A, "Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression", Cell Rep, 19, pp.1189~1201 (2017)
  23. Toki M, "Immune marker profiling and PD-L1, PD-L2 expression mechanisms across non-small cell lung cancer mutations", J Clin Oncol, 35(Supp), pp.abstr9076~ (2017)
  24. Dail M, "Distinct patterns of PD-L1 and PD-L2 expression by tumor and non-tumor cells in patients with MM, MDS and AML", Blood, 128, pp.1340~ (2016)
  25. Bang A, "Multicenter evaluation of the tolerability of combined treatment with PD-1 and CTLA-4 immune checkpoint inhibitors and palliative radiation therapy", Int J Radiat Oncol Biol Phys, 98, pp.344~351 (2017)
  26. Yunyuan Li, "Increased expression of PD-L1 and PD-L2 in dermal fibroblasts from alopecia areata mice", Journal of Cellular Physiology, 233(3), pp.2590~2601 (2018), Wiley-Blackwell[DOI]
  27. Hirose T, "PD-L1", PD-L2-expressing B-1 cells inhibit alloreactive T cells in mice, 2017, pp.12, e0178765~
  28. Loke P, "PD-L1 and PD-L2 are differentially regulated by Th1 and Th2 cells", Proc Natl Acad Sci U S A, 100, pp.5336~5341 (2003)
  29. Rizvi NA, "Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial", Lancet Oncol, 16, pp.257~265 (2015)
  30. Borghaei H, "Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer", N Engl J Med, 373, pp.1627~1639 (2015)
  31. Herbst RS, "Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial", Lancet, 387, pp.1540~1550 (2016)
  32. Fehrenbacher L, "Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial", Lancet, 387, pp.1837~1846 (2016)
  33. Rizvi NA, "Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer", J Clin Oncol, 34, pp.2969~2979 (2016)
  34. Carbone DP, "First-line nivolumab in stage IV or recurrent non-small-cell lung cancer", N Engl J Med, 376, pp.2415~2426 (2017)
  35. "Pembrolizumab (immunotherapy drug) in combination with guadecitabine and mocetinostat (epigenetic drugs) for patients with advanced lung cancer"[URL]
  36. Leora Horn, "Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non–Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057)", Journal of Clinical Oncology, 35(35), pp.3924~3933 (2017), American Society of Clinical Oncology (ASCO)[DOI]
  37. Rittmeyer A, "Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial", Lancet, 389, pp.255~265 (2017)
  38. Maio M, "Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial", Lancet Oncol, 18, pp.1261~1273 (2017)
  39. Calabrò L, "Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial", Lancet Oncol, 14, pp.1104~1111 (2013)
  40. Lu J, "Clinical evaluation of compounds targeting PD-1", PD-L1 pathway for cancer immunotherapy, 2015, pp.21, 451~467
  41. Reinmuth N, "Immunotherapy for lung cancer", Oncol Res Treat, 39, pp.360~368 (2016)
  42. de Mello RA, "Potential role of immunotherapy in advanced non-small-cell lung cancer", Onco Targets Ther, 10, pp.21~30 (2016)
  43. Steven A, "Immunotherapy for lung cancer", Respirology, 21, pp.821~833 (2016)
  44. Garon EB, "Pembrolizumab for the treatment of non-small-cell lung cancer", N Engl J Med, 372, pp.2018~2028 (2015)
  45. Monteiro ID, "Immunotherapy with checkpoint inhibitors for lung cancer: novel agents, biomarkers and paradigms", Future Oncol, 12, pp.551~564 (2016)
  46. Wrangle J, "Alterations of immune response of non-small cell lung cancer with azacytidine", Oncotarget, 4, pp.2067~2079 (2013)
  47. Ahuja N, "Epigenetic therapeutics: a new weapon in the war against cancer", Annu Rev Med, 67, pp.73~89 (2016)
  48. Kaufman HL., "Rational combination immunotherapy: understand the biology", Cancer Immunol Res, 5, pp.355~356 (2017)
  49. Sacco PC, "The combination of new immunotherapy and radiotherapy: a new potential treatment for locally advanced non-small cell lung cancer", Curr Clin Pharmacol, 12, pp.4~10 (2017)
  50. Davies AM, "Phase II trial of autologous cancer vaccine, CG8123 (GVAX), in patients with advanced bronchioloalveolar carcinoma (BAC): a Southwest Oncology Group Study (S0310)", J Thorac Oncol, 2, pp.S461~ (2007)
  51. Johnson DB, "Immune checkpoint inhibitors in NSCLC", Curr Treat Options Oncol, 15, pp.658~669 (2014)
  52. Raval RR, "Tumor immunology and cancer immunotherapy: summary of the 2013 SITC primer", J Immunother Cancer, 2, pp.14~ (2014)
  53. Shepherd FA, "Immunotherapy for non-small cell lung cancer: novel approaches to improve patient outcome", J Thorac Oncol, 6, pp.1763~1773 (2011)
  54. Kono K., "Current status of cancer immunotherapy", J Stem Cells Regen Med, 10, pp.8~13 (2014)
  55. Gubin MM, "Tumor neoantigens: building a framework for personalized cancer immunotherapy", J Clin Invest, 125, pp.3413~3421 (2015)
  56. Rizvi NA, "Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer", Science, 348, pp.124~128 (2015)
  57. Schumacher TN, "Neoantigens in cancer immunotherapy", Science, 348, pp.69~74 (2015)
  58. Desrichard A, "Cancer neoantigens and applications for immunotherapy", Clin Cancer Res, 22, pp.807~812 (2016)
  59. Atanackovic D, "Cancer-testis antigens MAGE-C1", CT7 and MAGE-A3 promote the survival of multiple myeloma cells, 2010, pp.95, 785~793
  60. Sienel W, "Melanoma associated antigen (MAGE)-A3 expression in stages I and II non-small cell lung cancer: results of a multi-center study", Eur J Cardiothorac Surg, 25, pp.131~134 (2004)
  61. Yang XN, "Single nucleotide polymorphisms of MAGE-A3 gene and its clinical implications in Chinese patients with non-small cell lung cancer (NSCLC)", Chin J Cancer Res, 27, pp.301~308 (2015)
  62. Vansteenkiste JF, "Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial", Lancet Oncol, 17, pp.822~835 (2016)
  63. Neninger E, "Combining an EGF-based cancer vaccine with chemotherapy in advanced nonsmall cell lung cancer", J Immunother, 32, pp.92~99 (2009)
  64. Massarelli E, "Immunotherapy in lung cancer", Transl Lung Cancer Res, 3, pp.53~63 (2014)
  65. Nemunaitis J, "Phase II study of belagenpumatucel-L, a transforming growth factor beta-2 antisense gene-modified allogeneic tumor cell vaccine in non-small-cell lung cancer", J Clin Oncol, 24, pp.4721~4730 (2006)
  66. Morris JC, "Potential chemo-sensitization effect of tergenpumatucel-L immunotherapy in treated patients with advanced non-small cell lung cancer (NSCLC)", J Clin Oncol, 31(Suppl), pp.abstr8094~ (2013)
  67. Ramlau R, "A phase II study of Tg4010 (Mva-Muc1-Il2) in association with chemotherapy in patients with stage III", IV Non-small cell lung cancer, 2008, pp.3, 735~744
  68. Yang L, "Immunotherapy for lung cancer: advances and prospects", Am J Clin Exp Immunol, 5, pp.1~20 (2016)
  69. Quoix E, "Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial", Lancet Oncol, 12, pp.1125~1133 (2011)
  70. Digumarti R, "A randomized, double-blind, placebo-controlled, phase II study of oral talactoferrin in combination with carboplatin and paclitaxel in previously untreated locally advanced or metastatic non-small cell lung cancer", J Thorac Oncol, 6, pp.1098~1103 (2011)
  71. Sahin U, "Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer", Nature, 547, pp.222~226 (2017)
  72. Ott PA, "An immunogenic personal neoantigen vaccine for patients with melanoma", Nature, 547, pp.217~221 (2017)
  73. Coulie PG, "Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy", Nat Rev Cancer, 14, pp.135~146 (2014)
  74. Heemskerk B, "The cancer antigenome", EMBO J, 32, pp.194~203 (2013)
  75. Ito A, "Cancer neoantigens: a promising source of immunogens for cancer immunotherapy", J Clin Cell Immunol, 6, pp.322~ (2015)

이 간행물의 다른 논문 (8건)

Lineage Differentiation Program of Invariant Natural Killer T Cells권동일, 이유정pp. 365-377Serosal Cavities Contain Two Populations of Innate-like integrin α4highCD4+ T Cells, Integrin α4β1+α6β1+α4β7− and α4β1+α6β1−α4β7+ Cells박찬호, 김태진, 서경석, 고인성, 이수진, 양정인pp. 392-401Polyvinylidene Fluoride Alters Inflammatory Responses by Activation-induced Cell Death in Macrophages박태원, 김상훈, 김현경, 정용우, 최수안, 김택승, 원란, 박희등pp. 402-409Terminally Differentiating Eosinophils Express Neutrophil Primary Granule Proteins as well as Eosinophil-specific Granule Proteins in a Temporal Manner김가람, 박성우, 김성민, 정윤재, 정일엽, 황새미pp. 410-423Species Specific Antiviral Activity of Porcine Interferon-α8 (IFNα8)김주희, 조승현, 김영현, 박은주, 김희준, 전현정, 이중복, 최인수, 곽아름, 강용선, Tam T.Nguyen, 김은혜, 김시내, 이시영, 김수현pp. 424-436
원문 보기